ASTH vs SSII

ASTH's Piotroski F-Score of 6/9 indicates a stable but not strong financial foundation, with notable weaknesses in profitability and cash flow generation. The absence of an Altman Z-Score raises concern about default risk, particularly given a high debt/equity ratio of 1.96 and negative earnings growth of -97.7% YoY. While the company exhibits explosive revenue growth (99.7% YoY) and strong earnings surprises in recent quarters, these are not sustainable without improving margins and profitability. The stock trades at a forward P/E of 9.64 but a current P/E of 107.00, suggesting a massive valuation disconnect that reflects overpricing relative to current earnings. The Graham Number of $8.19 and intrinsic value of $1.33 imply severe overvaluation, with the current price of $20.33 trading at a significant premium.

SSII exhibits critical financial instability, highlighted by a Piotroski F-Score of 0/9, indicating failure across all fundamental health markers. While the company shows explosive revenue growth (79.1% YoY), this is decoupled from profitability, with a net profit margin of -28.54% and a severe valuation disconnect (P/S of 23.04). The stock is in a clear technical downtrend, having lost nearly 50% of its value in the last six months. Without a path to profitability or a correction in valuation, the current price is unsustainable.